Roche Holding's stocks have seen ups and downs - a fitful drop following unfortunate fatalities during Elevidys dosing made headlines, along with the company's stock trading lower with a drop in pharma giants. However, an uplifting upturn occured when Maia Biotechnology signed a clinical supply deal with Roche, causing shares to rise. Also, Roche delivered positive
96-week results for their multiple sclerosis candidate, fenebrutinib. Investors remained hopeful with news about Swiss stocks, including Roche, painted a promising picture for June 17. Roche's shares popped 4% following their $5.3 billion obesity drug deal with Zealand Pharma. A
major acquisition of Poseida Therapeutics where Roche successfully tendered 66% of the shares also gave stocks a boost. Nevertheless, stocks slipped when Roche inked another obesity drug deal with Zealand. The company's outlook improved with a boost from a Phase 3 move for Prothena. However, Roche's stock did suffer a setback with a decline in trial updates for Ocrevus and reported side effects from its obesity trial affecting the stock's performance adversely. Despite these hiccups, Roche is reportedly outpacing its medical peers this year, and there's speculation about the sustainability of its growth.
Roche Stocks News Analytics from Wed, 17 Jul 2024 07:00:00 GMT to Wed, 18 Jun 2025 16:09:08 GMT -
Rating 1
- Innovation -2
- Information 8
- Rumor -1
